agreed. and a lot of shorting for "easy money." i'm trying to look down the line. so i'm wondering what else is in the pipeline. i can afford to hold this stock for three years. and i'm wondering if there are any potential developments in the pipeline to get it to, say, $10.
the way it's trading. but too many retailers trade on emotion. it's why a lot of 'em bought at insane prices. but i always assumed that this company wasn't a one-trick pony. that it had other things in the works, although not yet approved. i'm looking down the line.
analysts have lost all credibility after the insane price targets of $100, etc. they were telling retailers to buy in the 40s, and now some analysts are saying sell here. so i get your point. but at this juncture no one trusts the analysts or the CEO until there's a concrete positive development.
let's assume the worst: that the drug will never make it in the US, and now faces a pricing challenge and limited use/profits in europe, especially germany. but i'm curious about the pipeline. what are PCTC's most promising alternatives -- future drugs. is there anything in there -- any potential pipeline development -- that could get this thing back to $10 in the new few years? and is it way too early -- or unrealistic -- for big pharma to buy the company mainly for its pipeline? lots of institutional buyer and big-money investors are getting slaughtered on this. i'd think there'd inevitably be a push for a sale to salvage some value. no?
bottom line: CLBS rarely trades pre-market. and in less than four hours during the slowest trading day of the year, it surpassed the daily average. we'll see what next week brings.
thanks for the insight. well, for some reason, several media outlets latched on to the news FRI a.m., leading to some unusual pre-market buys on the slowest trading day of the year.
very new. you'll have to google the "end of daily injections" for a host of news articles this morning, but here's an excerpt from the daily telegraph -- based in england:
and i meant university of california -- not stanford -- in my earlier post (along with yale).
several news articles that the type 1 diabetics will no longer need to use daily insulin injections. google it. CLBS in partnership with yale and stanford. phase 1 trial with 14 candidates very promising. they should have had some type of news release. maybe it'll come MON.
the most bizarre thing about the stock is that every single analyst was bullish despite all the debt. and they seemed blindsided by the last earnings report. the stock can bounce back. was just way overpriced. crazy that folks were buying in the $20s with so much heavy insider selling from jump.
good points as usual. i learned from ALNY. got in early. sold at $20ish when CEO seemed to be dumping. stock quadrupled over the next several months.
the CEO's heavy selling seems like more of a red flag than the tweet. jacosa, what's your take? some other poster said the CEO barely has any shares left. and dumped most of them. insiders sell for various reasons but the amount and timing of it seems ominous.